NCT01074099

Feasibility Study of BMAC Enhanced CABG

Feasibility Study of Autologous Concentrated Bone Marrow Nucleated Cell Therapy for Congestive Heart Failure Patients Undergoing Treatment With Coronary Artery Bypass Grafting(CABG) Surgery

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Harvest Technologies · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients undergoing CABG will have 60 mL of bone marrow drawn, concentrated in a SmartPRep2 centrifuge and have the concentrated nucleated cells injected into areas of ischemic myocardium

Detailed description

Patients undergoing CABG will have 60 mL of bone marrow drawn, concentrated in a SmartPRep2 centrifuge and have the concentrated nucleated cells injected into areas of ischemic myocardium. Control subjects will undergo CABG only

Conditions

• Congestive Heart Failure

Interventions

Type	Name	Description
BIOLOGICAL	BMAC	Injection of BMAC into ischemic myocardium during CABG
PROCEDURE	CABG only	Control subjects will undergo CABG surgery without BMAC injection

Timeline

• Start date: 2011-02-01
• Primary completion: 2013-04-01
• Completion: 2013-04-01
• First posted: 2010-02-24
• Last updated: 2016-01-18
• Results posted: 2016-01-18

Locations

2 sites across 1 country: United States